IPASS
Iressa Pan-Asia Study
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 1,217 Asian, never/light-smoker patients with advanced lung adenocarcinoma, gefitinib improved progression-free survival in the EGFR-mutation-positive subgroup compared with carboplatin + paclitaxel.
N
1 217
Schéma
Open-label RCT
Critère
Progression-free survival
Pertinence
1
RésultatOverall PFS HR 0.74. EGFR-mutated: HR 0.48; EGFR wild-type: HR 2.85 — striking qualitative interaction.
Mok TS, et al. N Engl J Med. 2009;361(10):947-957. 10.1056/NEJMoa0810699
Discussion et critique
Foundational trial of precision oncology — mandated EGFR-mutation testing before first-line therapy in advanced NSCLC.